Evidence map›Paper›PMID 42656315›Full record

ArticleFrontiers in oncology2026

Predictive value of

Jing Wang, Yiyuan Dong, Ningjun Xu, Xiaowei Ma, Ying Liu, Qian Zhao

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jing Wang *General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Yiyuan Dong *General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Ningjun XuDivision of Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Macau, Macau SAR, China.
Xiaowei MaGeneral Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Ying LiuGeneral Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Qian ZhaoGeneral Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the predictive value of tabular deep learning models trained on handcrafted Material and methods: We retrospectively analyzed 112 non-CNS DLBCL patients who underwent brain Results: The AutoInt and Neural Oblivious Decision Ensembles (NODE) models showed the best predictive performance, achieving training areas under the curve (AUCs) of 0.905 and 0.904, and test AUCs of 0.858 and 0.808, respectively. DCA suggested potential clinical utility. In the modality-specific analysis, the AutoInt model integrating CT, PET, and clinical features achieved a training AUC of 0.905 and a test AUC of 0.858, representing the most favorable test-set performance among the evaluated AutoInt input modalities. A CT texture feature from the left occipital lobe emerged as the highest-ranked model contributor in SHAP analysis, with a mean absolute attribution score of approximately 0.0078. Conclusions: Tabular deep learning models based on handcrafted PET/CT PyRadiomics features showed preliminary potential for predicting CRCI in patients with non-CNS DLBCL. Among the evaluated models, AutoInt achieved the most favorable performance in the exploratory internal test set. Multimodal integration of PET, CT, and clinical tabular features may provide complementary information for CRCI prediction. SHAP analysis identified a left occipital CT texture feature as the top-ranked model contributor; however, this finding should be regarded as exploratory rather than a validated biomarker.

Indexed as

18F-fluorodeoxyglucosecancer-related cognitive impairmentdiffuse large B-cell lymphomaPyRadiomics featuresSHAPtabular deep learning

Identifiers

PMID42656315
PMCPMC13506380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.